REGISTRI: Regorafenib in first-line of KIT/PDGFRA wild type metastatic GIST: a collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial.

Mol Cancer · 2023 · PMC10413507 · PMID 37559050

Europe PMC DOI

hedged sentence

0.3100

closest p · 6.2× alpha

0.3100

boldest claim

The sentences

showed a trendp = 0.31not close (p > 0.1)

In addition, SDH-deficient GIST showed a trend toward a longer OS compared with SDH-proficient GIST, NR vs. 28.7 months (p = 0.31) (Additional File 8 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.